Meiji Seika Kaisha, Ltd.

Harumi Fukuyasu

Tsutomu Tsuruoka

Takashi Tsuruoka

Shigeharu Inouye

Haruo Yamamoto

Shinichi Kondo

Takashi Shomura

Masao Koyama

Satoru Nakabayashi

Yuzo Kazuno

Yuuko Ishii

Masaji Sezaki

Tetsuro Watanabe

Tomizo Niwa

Yasuharu Sekizawa

Hiromi Watanabe

Tatsuo Ito

Zenichiro Ohya

Katsuo Kawakami

Takahiko Kikuchi

Katsumi Kawaharajo

Kazunori Oba

Tumor growth in a mammal is inhibited by the administration of an effective amount of xanthocillin X dimethylether. The xanthocillin X dimethylether is administered in a range of 10-3,000 milligrams per day for an average adult human patient. The xanthocillin X dimethylether can be administered orally, by direct application into a neoplastic lesion, or by other parenteral forms of administration including intravenous, subcutaneous, or intramuscular injections. Also, suppository forms can be used.

Method of inhibiting tumor growth using xanthocillin X dimethylether

Sugar lactams such as N-(3-phenylpropyl)-1-deoxynojirimycin, 1-deoxynojirimycin, D-glucaro-.delta.-lactam, 6-O-triphenylmethyl-D-gluco-.delta.-lactam, etc., and new derivatives thereof which inhibit metastasis of cancer cells.

Cancer cell metastasis inhibitor methods

A xanthocillin X monomethyl ether derivative represented by the formula (I) ##STR1## wherein R represents an alkyl group, an alkenyl group, an alkoxycarbonyl group, an aralkyl group, an alkyl group substituted with a pyridyl group or a halogen atom, an aralkyl group substituted with an alkyl group or a halogen atom, or an aroyl group, which exerts an intense effect of inhibiting the proliferation of a tumor, in particular, a solid tumor.

Xanthocillin X monomethyl ether derivative and antitumor agent

Sugar lactams such as N-(3-phenylpropyl)-1-deoxynojirimycin, 1-deoxynojirimycin, D-glucaro-.delta.-lactam, 6-O-triphenylmethyl-D-gluco-.delta.-lactam, etc. and new derivatives thereof which markedly inhibit metastasis of cancer cells.

Cancer cell metastasis inhibitors and novel compounds

Disclosed is an antiviral agent comprising as an active component a substance SF-2140 described in detail in the specification, and a pharmaceutically acceptable carrier. Also disclosed is a method for treatment of viral diseases comprising administering a pharmaceutically effective amount of the substance SF-2140.

Antiviral agents

A new antiviral agent is now provided, which contains as the active ingredient at least one known glycine derivative of the formula: ##STR1## wherein R is a hydrogen atom, R' is a group --CH.sub.2 NH.sub.2, --CH.sub.2 NHCONH.sub.2, --CH.sub.2 NHCONHOH, --CH.sub.2 CH.sub.2 PO(OH).sub.2, ##STR2## or R and R' taken together form a group ##STR3## and R' is a hydrogen atom or a lower alkyl group, or a pharmaceutically acceptable salt of said glycine derivative. This antiviral agent is useful for therapeutic prevention and treatment of diseases caused by various kinds of viruses.

Antiviral agent and treatment of viral infections

Growing community of inventors

Yokohama, Japan

Harumi Fukuyasu